IL6 and atherosclerosis: Recently, the Trial to Evaluate Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilising Antibody-Mediated IL-6 Inhibition (RESCUE) trial successfully demonstrated that the inhibition of IL-6 via ziltivekimab substantially reduced atherosclerosis-associated inflammation and thrombosis with minimal effect on platelet counts [187,188].